Vol. 7, Issue 2, Part C (2025)

Objectives: To evaluate the efficacy of the Unani formulation in regulating the biochemical markers (Serum Uric Acid, Calcium and Haemoglobin Levels) among PIH (Zagatud-Dam Qawi Bawajeh Hamal) patients.

Materials and Methods: Diagnosed patient (n=40) were randomly allocated in 2 groups (A & B), Group A (n=20) received a Unani therapeutic regimen comprising Sufoof containing Jadwar and Ood-e-Saleeb, encapsulated in 500 mg capsules and administered at a dose of one capsule twice daily. Shirajaat formulation containing Tuqme Kahu, Tuqme Kaddu, Tuqme Khayarain, and Tuqme Khurf Siyah (4 g each) was given in a dosage of 15 ml twice daily. Additionally, Joshanda prepared from Barg-e-Gaozaban was administered twice daily.” Group A patients, diagnosed with PIH, received inpatient intensive Unani management for 10 days and were discharged upon complete normalization of clinical signs and biochemical parameters. In contrast, Group B included normotensive antenatal patients who received no therapeutic intervention and were monitored under routine prenatal care.” Results: Unani treatment initiated after confirmed hypertension showed rapid reduction in blood pressure following the first dose. Most patients achieved normal vaginal delivery with marked improvement in maternal condition. No adverse effects were reported, and complete recovery from hypertensive features was observed. Overall, the formulation was safe, effective, and well tolerated in pregnancy-induced hypertension.

Conclusion: The Unani formulation demonstrated safe, effective, and well-tolerated management of pregnancy-induced hypertension. Early initiation resulted in rapid blood pressure control, improved maternal outcomes, and successful normal deliveries without adverse effects. Its therapeutic efficacy in both subjective and objective parameters indicates that Unani medicine can be a valuable adjunct in the holistic management of PIH.